Association of multiple biomarkers of iron metabolism and type 2 diabetes: The EPIC-Inter act study

Diabetes Care

Volumn 39, Issue 4, 2016, Pages 572-581

  Podmore, Clara ^a   Meidtner, Karina ^b   Schulze, Matthias B ^b   Scott, Robert A ^a   Ramond, Anna ^c   Butterworth, Adam S ^c   Di Angelantonio, Emanuele ^c   Danesh, John ^c   Arriola, Larraitz ^d,e,f   Barricarte, Aurelio ^f,g   Boeing, Heiner ^b   Clavel Chapelon, Françloise ^h,i   Cross, Amanda J ^j   Dahm, Christina C ^k   Fagherazzi, Guy ^h,i   Franks, Paul W ^l,m   Gavrila, Diana ^f,n   Grioni, Sara ^o   Gunter, Marc J ^j   Gusto, Gaelle ^h,i   Jakszyn, Paula ^p   Katzke, Verena ^q   Key, Timothy J ^r   Kühn, Tilman ^q   Mattiello, Amalia ^s   Nilsson, Peter M ^l   Olsen, Anja ^t   Overvad, Kim ^k,u   Palli, Domenico ^v   Quirós, J Ramón ^w   Rolandsson, Olov ^m   Sacerdote, Carlotta ^x,y   Sánchez Cantalejo, Emilio ^f,z   Slimani, Nadia ^aa   Sluijs, Ivonne ^ab   Spijkerman, Annemieke M W ^ac   Tjonneland, Anne ^t   Tumino, Rosario ^ad,ae   Van Der A, Daphne L ^ac   Van Der Schouw, Yvonne T ^ab   Feskens, Edith J M ^af   Forouhi, Nita G ^a   Sharp, Stephen J ^a   Riboli, Elio ^j   Langenberg, Claudia ^a   Wareham, Nicholas J ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Public Health Division of Gipuzkoa   (Spain)

^e BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^h CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k AARHUS UNIVERSITY   (Denmark)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m UMEÅ UNIVERSITY   (Sweden)

ⁿ DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^q GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^t DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^u AALBORG UNIVERSITY HOSPITAL   (Denmark)

^v CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^w University of Turin and Center for Cancer Prevention ^*  (Spain)

^x UNIVERSITY OF TURIN   (Italy)

^y Human Genetics Foundation   (Italy)

^z UNIVERSITY OF GRANADA   (Spain)

^aa INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^ab UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ac NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ad CIVILE M P AREZZO HOSPITAL   (Italy)

^ae Associazone Iblea per la Ricerca Epidemiologica Onlus   (Italy)

^af WAGENINGEN UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IRON; TRANSFERRIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERFERRITINEMIA; INCIDENCE; IRON BLOOD LEVEL; IRON INTAKE; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; TRANSFERRIN SATURATION; AGED; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INCIDENCE; IRON; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSFERRIN; YOUNG ADULT;

EID: 84962074006     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0257     Document Type: Article

References (49)

1. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastro-enterology 2010;139:393-408, 408.e1-2
2. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012;87:155-160
3. Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes melli-tus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev 2013;29:308-318
4. Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a meta-analysis of observational studies. Diabetes Metab Res Rev 2014;30:372-394
5. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973;26:770-772
6. Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. BMJ 1972;4:206-208
7. Beutler E, Felitti V, Ho NJ, Gelbart T. Relationship of body iron stores to levels of serum fer-ritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol 2002;107:145-149
8. Haap M, Fritsche A, Mensing HJ, Häring HU, Stumvoll M. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med. Ann Intern Med 2003;139:869-871
9. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 1990;36: 1350-1355
10. Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012;29: 1098-1107
11. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitusand inflammation. Curr Diab Rep 2013;13:435-444
12. Worwood M. The laboratory assessment of iron status-an update.Clin Chim Acta 1997;259: 3-23
13. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012;366:348-359
14. Brissot P, Ropert M, LeLan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012;1820:403-410
15. Langenberg C, Sharp S, Forouhi NG, et al.; InterAct Consortium. Design and cohort description of the InterAct Project:an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 2011;54:2272-2282
16. Peters T, Brage S, Westgate K, et al.; InterAct Consortium. Validity of a short questionnaire to assess physical activity in 10 European countries. Eur J Epidemiol 2012;27:15-25
17. Westgard rules [Internet], 2009. Madison, WI, Westguard QC. Available from http://www .westgard.com/mltirule.htm. Accessed 25 January 2016
18. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22
19. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384
20. Lean ME, Han TS, Morrison CE. Waist cir-cumferenceas a measure forindicating need for weight management. BMJ 1995;311:158-161
21. Jung CH, Lee MJ, Hwang JY, et al. Elevated serum ferritin level is associated with the incident type 2 diabetes in healthy Korean men: a 4 year longitudinal study. PLoS One 2013;8: e75250
22. Lee B-K, Kim Y, Kim Y-I. Association of serum ferritin with metabolic syndrome and diabetes mellitus in the South Korean general population according to the Korean National Health and Nutrition Examination Survey 2008. Metabolism 2011;60:1416-1424
23. Fumeron F, Péan F, Driss F, et al.; Insulin Resistance Syndrome (DESIR) Study Group. Fer-ritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006;29:2090-2094
24. Mainous AG 3rd, King DE, Pearson WS, Garr DR. Is an elevated serum transferrin saturation associated with the development of diabetes? J Fam Pract 2002;51:933-936
25. Ellervik C, Mandrup-Poulsen T, Andersen HU, et al. Elevated transferrin saturation and risk of diabetes: three population-based studies. Diabetes Care 2011;34:2256-2258
26. Cheung CL, Cheung TT, Lam KS, Cheung BM. High ferritin and low transferrin saturation are associated with pre-diabetes among a national representative sample of U.S. adults. Clin Nutr 2013;32:1055-1060
27. Park RJ, Moon JD. Low transferrin saturation is associated with impaired fasting glucose and insulin resistance in the South Korean adults: the 2010 Korean National Health and Nutrition Examination Survey. Diabet Med 2015;32:673-678
28. Huth C, Beuerle S, Zierer A, et al. Bio-markers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: the KORA F4 study. Eur J Endocrinol 2015;173:643-653
29. Szöke D, Panteghini M. Diagnostic value of transferrin. Clin Chim Acta2012;413:1184-1189
30. Lee D-HD-H, LiuDY, Jacobs DR Jr, et al. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 2006;29:1090-1095
31. Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-97
32. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-1163
33. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001;116:263-270
34. Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-2354
35. Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007;50:949-956
36. Gabrielsen JS, Gao Y, Simcox JA, et al. Adi-pocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012;122:3529-3540
37. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is prospectively associated with insulin resistance and glucose intolerance over a 7-year follow-up period: the CODAM study. Acta Diabetol 2015;52:337-348
38. O'Riordain MG, Ross JA, Fearon KC, et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995;269:E323-E330
39. Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987;262:8975-8980
40. Vargas L, Kawada ME, Bazaes S, et al. Insulin antagonism: a novel role for human serum transferrin. Horm Metab Res 1998;30:113-117.
41. Hanley AJ, Williams K, Festa A, et al.; Insulin Resistance Atherosclerosis Study. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004;53:2623-2632
42. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378:169-181
43. Adams PC, McLaren CE, Speechley M, McLaren GD, Barton JC, Eckfeldt JH. HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level ,1000 mg/L. Can J Gastroenterol 2013;27:390-392
44. Adams PC, Reboussin DM, Barton JC, et al.; Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769-1778
45. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230
46. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-. A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218
47. RongY, BaoW, RongS, et al. Hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a meta-analysis. Am J Epidemiol 2012;176:461-472
48. Zhang D, Jiang X, Wu Y, Jiang W, Pang Z. Re: "hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a metaanalysis". Am J Epidemiol 2013;177:372-373
49. Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med 2008;358:291-292